1471-2334-9-200 1471-2334 Case report <p>Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies</p> Malvy Denis denis.malvy@chu-bordeaux.fr Ezzedine Khaled khaled.ezzedine@chu-bordeaux.fr Mamani-Matsuda Maria maria.mamani-matsuda@u-bordeaux2.fr Autran Brigitte brigitte.autran@psl.ap-hop-paris.fr Tolou Hugues tolouh@imtssa.fr Receveur Marie-Catherine marie-catherine.receveur@chu-bordeaux.fr Pistone Thierry thierry.pistone@chu-bordeaux.fr Rambert Jérome jerome.rambert@u-bordeaux2.fr Moynet Daniel daniel.moynet@u-bordeaux2.fr Mossalayi Djavad djavad.mossalayi@u-bordeaux2.fr

Travel Clinics and Tropical Disease Unit, Department of Internal Medicine, Infectious Diseases and Tropical Medicine, University Hospital Center, Bordeaux, F-33075 France

Centre René Labusquière (Tropical Medicine and Hygiene Branch), University Bordeaux, Bordeaux, F-33076, France

PPF Parasitology, University Bordeaux 2, Bordeaux, F-33076, France

Laboratory of Immunity and Infection, UMR-S INSERM 945, University Pierre and Marie Curie, Hôpital Pitié-Salpêtrière, 83, Boulevard de l'hôpital, Paris F-75651, France

Laboratory of Virology, French Armed Forces Institute of Tropical Medicine (IMTSSA), Allée du Médecin colonel Eugène Jamot, Le Pharo, BP 60109, 13262 Marseille Cedex 07, France

BMC Infectious Diseases 1471-2334 2009 9 1 200 http://www.biomedcentral.com/1471-2334/9/200 10.1186/1471-2334-9-200 20003320
21 6 2009 10 12 2009 10 12 2009 2009 Malvy et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Chikungunya fever is an emerging arboviral disease characterized by an algo-eruptive syndrome, inflammatory polyarthralgias, or tenosynovitis that can last for months to years. Up to now, the pathophysiology of the chronic stage is poorly understood.

Case presentation

We report the first case of CHIKV infection with chronic associated rheumatism in a patient who developed progressive erosive arthritis with expression of inflammatory mediators and persistence of specific IgM antibodies over 24 months following infection.

Conclusions

Understanding the specific features of chikungunya virus as well as how the virus interacts with its host are essential for the prevention, treatment or cure of chikungunya disease.

Background

Chikungunya virus (CHIKV) is an enveloped positive-strand RNA alphavirus which can infect human epithelial and endothelial cells, fibroblasts or macrophages 12. A CHIKV epidemic recently occurred on islands of the Indian Ocean in 2005 345. CHIKV infection may cause an algoeruptive syndrome with disabling joint pain and recurrent rheumatic manifestations 678. Until now, it has been assumed that complete recovery occurs, even when symptoms are long lasting. Remarkably, despite the severity and duration of arthritis, articular destruction has been reported very rarely 9. We report the case of a patient with CHIKV infection presenting with severe chronic rheumatism accompanied by progressive destructive arthritis and dysregulated expression of inflammatory mediators.

Case presentation

In November 2005, a 60-year-old French man living in La Réunion experienced an acute influenza-like illness with diffuse arthralgia affecting bilaterally the distal inter-phalangeal joints of the fingers and the toes with hand tenosynovitis. His past medical history was unremarkable with no family history of inflammatory rheumatism.

Serology demonstrated the presence of anti-CHIKV IgM and confirmed the diagnosis of CHIKV infection. During the following months, the patient had persisting inflammatory arthralgia and joint stiffness which were not improved by symptomatic treatment. One year later, he developed refractory tenosynovitis in the wrists.

On February 15, 2007, the patient returned to France and consulted in our department. He complained of persistent symmetrical inflammatory arthritis of the wrists with fixed oedema of the two hands predominating on the right. Hand synovitis of the extensors and the flexors of wrists and fingers were noted. Lymphocyte immunophenotyping showed an increased CD4 T-cell count at 1,18 × 109/L (63.5%) and an activated CD45/CD3 (-) T-cell count at 0.209 × 109/L (11.3%), and CD45/CD3 (+) at 0,119 × 109/L (6.4%). Serum immunoglobulin was normal, as were the C3 and C4 complement fractions. No markers of autoimmunity were found, notably anti-citrullin peptide antibodies, antinuclear antibodies or cryoglobulinemia. The HLA B27 gene was positive and HLA system class II genotyping revealed an HLA-DRB1.03.11 genotype.

At the time of the consultation, serologic status for CHIKV antibodies was reevaluated using IgM-capture and an IgG-capture enzyme-linked immunoabsorbent assay with inactivated cell-culture-ground chikungunya virus and mouse anti-chikungunya hyperimmune ascitic fluid (Institut Pasteur, Lyon, France). Persistent specific anti-CHIKV IgM was detected in this late stage serum sample, collected 18 months after the infection, with optical density (OD) values of 1.47 for IgG and 0.81 for IgM. Testing for CHIKV RNA was negative 10. Radiography of the hands and wrists showed a subchondral defect of the 2nd and 3rd right proximal interphalangeal finger joints as well as of the 3rd, 4th and 5th left distal interphalangeal joints. Magnetic resonance imaging (MRI) of the hands and wrists revealed marked bilateral periostal inflammation and oedematous carpitis (Fig 1A and 1B), with carpis synovitis (1C) and bone destruction in the left hand (1D) accompanied by intra-articular swelling (1D). Bone scintigraphy revealed diffuse inflammation of several joints, prominent in the right wrist (3rd metacarpo-phalangeal joint) (Fig 1E) and the left ankle (1F), as well as evolutive enthesopathy of the left calcaneum. Methotrexate (MTX) was initiated at the dose of 17.5 mg/week and four months later, dramatic improvement was observed in both the number and state of swollen and tender joints and in tendon involvement. At this time, MRI of the hands, wrists and feet showed reduced progression of erosion and a decrease in radiographic inflammation and oedematous damage compared to before treatment. Clinical and radiological improvement was maintained over 15 months. At this end-point, CHIKV antibody serology showed persistence of both specific IgM and IgG, with OD values of 0.60 and 0.32, respectively.

<p>Figure 1</p>

Magnetic resonance imaging (MRI) and bone scintigraphy of the hands and wrists of a 60-year-old man with chikungunya virus infection revealing

Magnetic resonance imaging (MRI) and bone scintigraphy of the hands and wrists of a 60-year-old man with chikungunya virus infection revealing. A. Arthritis of the 3rd metacarpo-phalangeal joint of the right hand with extensor tenosynovitis associated with intra-articular swelling (red arrow on axial section, time-resolved contrast-enhanced T1-weighted sequence after Gadolinium injection with fat suppression) B. Bilateral periostum inflammation and oedematous carpitis with synovitis predominating on the left hand (arrow on axial section, time-resolved-enhanced T2-weighted sequence with fat suppression) C. Asymmetric inflammatory carpitis with multiple synovitis of flexors of the left wrist (red arrows on axial section, time-resolved contrast-enhanced T1-weighted sequence after Gadolinium injection with fat suppression) D. Bone destruction on the left hand (red arrows on coronal section, time-resolved contrast-enhanced T1-weighted sequence with fat suppression) E. Bone scintigraphy of the wrists and hands showing an intense focus of technetium 99 m-labeled methylene disphosphonate tracer uptake, particularly in the right metacarpo-phalangeal wrist. F. Bone scintigraphy of the left foot showing an intense focus of technetium 99 m-labeled methylene disphosphonate tracer uptake, particularly in the left ankle.

Immunological evaluation

T cell function was assessed using proliferation assays and ELISPOT quantification of interferon-γ (IFN-γ) production by T cells. No proliferative response or IFN-γ production could be detected in response to CHIKV antigens derived from an in-house preparation of β-propionolactone-inactivated virus (French Armed Forces Institute of Tropical Medicine, Marseilles, France). T cell viability was ascertained by concurrent detection in the same assays of T cells responding to candidin and herpes simplex virus-1 antigens tested as controls.

Peripheral blood lymphocytes (PBL) from the patient and from three healthy control individuals were isolated and analysed at a transcriptomic level using real-time reverse transcriptase-polymerase chain reaction (PCR) to detect mRNA species encoding inflammatory mediators (RT2 Profiler™ PCR Array Human Inflammatory Cytokine and Receptors, SuperArray, Frederick, USA). Each PCR used the same quantity of total RNA from each cell culture and the absence of a signal after 35 PCR cycles was taken as the threshold for the mRNA not being detectable. These PCR analyses were completed by measurement of cytokine levels in the serum and in the 48 h PBL-derived supernatant. These analyses were performed on samples obtained before treatment initiation and at the four-month follow-up.

At baseline, characteristic up regulation of mRNAs encoding pro-inflammatory mediators, including TNF-α, LTA, CRP, IL-1A and IL-17C was observed in PBL from the patient (Table 1). In addition, these cells expressed high levels of mRNAs encoding chemokines (IL-8, CCL1, CCL7, CCL8, CCL16, CCL24, CCL26, and CXCL5) or their receptors (XCR1, CCR2, CCR6, CCR8, and CCR9). In contrast, the expression of genes encoding CD40 Ligand (CD40L), IFN-α, IL-22, CXCL2 and CXCL14 was not detected. High levels of the pro-inflammatory cytokines IL-1β, IL-6, IL-8 and IL-10 were detected in the supernatant following 48 h incubation of PBLs in culture medium alone, while comparatively low levels of IFN-γ and TNF-α were found. On the contrary, IFN-α, IL-4 or IL-5 were not detected in cell supernatant (Table 2).

<p>Table 1</p>

Gene expression profile in a patient with chikungunya virus infection before and four months following methotrexate (MTX) treatment.

Gene Name

Unigene ID

Description

Before MTX Fold/Control

After MTX Fold/Control

Before/after Fold ††


Inflammatory mediators


TNF-α

241570

Tumor necrosis factor-α (TNFsuperfamily, member 2)

9†

-15

-135


LTA

36

Lymphotoxin alpha (TNF superfamily, member 1)

1

-10

-13


CRP

76452

C-reactive protein, pentraxin-related

12

-3

-33


IL-1A

1722

Interleukin 1, alpha

2

-5

-9


IL-1F5

516301

Interleukin 1 family, member 5 (delta)

84

1

-90


IL-1F6

278910

Interleukin 1 family, member 6 (epsilon)

2

-9

-20


IL-1F7

166371

Interleukin 1 family, member 7 (zeta)

4

-3

-11


IL-1F8

278909

Interleukin 1 family, member 8 (eta)

7

-4

-28


IL-1F9

211238

Interleukin 1 family, member 9

8

-2

-20


IL-1RN

81134

Interleukin 1 receptor antagonist

49

-3

-167


IL-9

960

Interleukin 9

3

-6

-20


IL-9R

406228

Interleukin 9 receptor

5

-3

-15


IL-17C

278911

Interleukin 17C

10

1

-10


SPP1

313

Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)

7

-2

-15


C3

529053

Complement component 3

12.25

19

1


Th2-related factors


IL-13

845

Interleukin 13

5

-11

-55


IL-22

287369

Interleukin 22

OFF

OFF

--


CD40L

592244

CD40 ligand (TNF superfamily, hyper-IgM syndrome)

OFF

OFF

--


Inflammatory chemokines and their receptors


IFN-α

211575

Interferon-α2

OFF

OFF

--


IL-8

624

Interleukin 8

5

1

-5


XCR1

248116

Chemokine (C motif) receptor 1

34

-2

-62


CCL1

72918

Chemokine (C-C motif) ligand 1

4

-31

-109


CCL7

251526

Chemokine (C-C motif) ligand 7

3

-14

-40


CCL8

271387

Chemokine (C-C motif) ligand 8

2

-46

-80


CCL16

10458

Chemokine (C-C motif) ligand 16

6

-3

-22


CCL24

247838

Chemokine (C-C motif) ligand 24

76

-3

-190


CCL26

131342

Chemokine (C-C motif) ligand 26

7

-2

-15


CCR2

644637

Chemokine (C-C motif) receptor 2

13

89

7


CCR6

46468

Chemokine (C-C motif) receptor 6

4

-5

-17


CCR8

113222

Chemokine (C-C motif) receptor 8

8

-2

-19


CCR9

225946

Chemokine (C-C motif) receptor 9

5

-3

-15


CXCL2

590921

Chemokine (C-X-C motif) ligand 2

OFF

2

ON


CXCL5

89714

Chemokine (C-X-C motif) ligand 5

27

4

-7


CXCL14

483444

Chemokine (C-X-C motif) ligand 14

OFF

1

ON

Patient had persistent specific IgM antibodies and erosive arthritis for two years before treatment.

† gene expression in patient peripheral blood mononuclear cells compared to those observed in cells from three healthy controls using real-time RT-PCR. Results shown as fold expression compared to control values. Inflammatory arrays were performed using RT2 Profiler PCR Array System (Ref: APHS-011B, SuperArray, Frederick, USA, http://www.superarray.com

†† Comparison of gene expression before MTX treatment and following 4 months therapy

<p>Table 2</p>

Cytokine profiles from patient peripheral blood mononuclear cell supernatants before and four months following methotrexate (MTX) treatment.

pg/ml


Patient cells††

Cytokine

Healthy controls

Before MTX

After MTX


IFN-γ

0-10

13

<10


IL-1β

0-10

1 100

2


IL-6

0-35

9 482

864


IL-8

150-2000

1 4795

1094


IL-10

0-10

425

4


TNF-α

0-60

92

<10

Cytokine levels in supernatants from cells incubated 48 h in medium alone and quantified using FlowCytomix Human Th1/Th2 Kit as recommended (Bender Medsystems, Vienna, Austria, http://www.bendermedsystems.com).

†† No cytokine was detected in serum. IFN-α, IL-2, IL-4, IL-5 and IL-12 were not detected in these samples.

Four months following initiation of treatment, the expression of most of the above mRNAs was attenuated, and expression of CD40L, IFN-α and IL-22 remained undetectable. At this time, cytokine levels measured in the cell culture supernatant were markedly decreased and surface CD40L expression on peripheral blood cells could not be detected (data not shown).

Conclusions

Chikungunya virus infection is usually a self-limiting disease characterized by arthralgia with late peripheral joint pain in the smaller joints 1112. A sole case of late articular destruction after decades of post CHIKV-chronic rheumatism has been reported with a questionable relationship to the CHIKV infection 9. Our case is remarkable for the clearly erosive arthritis pattern accompanied with enthesopathies, which developed within less than two years of the index CHIKV infection 13.

The patient was positive for HLA B27 antigen although no clinical rheumatologic manifestations had been noted before the CHIKV infection. For this reason, we can conclude that he developed a form of spondylarthropathy. Concerning the acute phase, recent findings suggested that both classical and severe symptoms of chikungunya disease closely reflect CHIKV tissue tropism 14, with fibroblasts being the primary targets, as they are for other alphaviruses 115. The molecular basis of this tropism may combine specific interactions between virus and host cells and tissues, and an intrinsic lower ability of this cell type to control CHIKV infection 814.

The pathogenesis of persistent arthritis remains unclear although persistent infection of synovial macrophages has been documented for other alphaviruses 1617. Moreover, factors secreted by infected macrophages seem to play a pivotal role in joint inflammation 18. To date, the presence of CHIKV RNA in joints during the acute phase of infection has only been demonstrated in animal models 1419. CHIKV RNA has never been detected in joint tissues during the late phase, although it has been found in human muscle satellite cells three months after infection 2. Taken together with reports of the presence of long lasting IgM anti-CHIKV antibodies 20, these findings could indicate the persistence of CHIKV in certain host tissues or cells. However, there is no evidence that viral persistence is necessary to sustain chronic joint pathology after the infection. In our case, an antigen-specific immunopathology may underlie the development of chronic joint disease due to the presentation of specific autologous or microbial arthritogenic peptides 21. This would be consistent with the notion of an infectious trigger for immune activation derived from molecular mimicry which has been postulated as a potential pathogenic mechanism in autoimmunity 222324.

High levels of pro-inflammatory cytokines IL-1, IL-6 and IL-8 were detected in cell supernatants from the patient's lymphocytes and elevated expression of genes encoding a variety of cytokines and chemokines known to be implicated in the pathogenesis of arthritis were also observed 2526. In contrast, IFN-α, IL-4 and IL-5 were not detected in cell supernatants whereas IL-10 was increased. Of interest, the lymphocytes failed to express genes encoding IFN-α, IL-22 and CD40L, which are required for B cell differentiation, optimal immunoglobulin isotype switching and antiviral activity. Although the persistence of specific IgM antibodies has been documented after CHIKV infections 20, an association between these antibodies and disease severity has not been established. It is possible that antibody persistence may be determined by the persistence of virus in host tissues since, in acute arboviral infections, IgM are generally no longer detectable after 6-12 months. Unfortunately, in our case, it was not possible to perform RT-PCR for detection of CHIKV in synovial fluid or tissue

Viruses have evolved a number of mechanisms for suppressing host immune responses. In particular, viral proteins may suppress the retinoic acid-inducible gene I-like helicase and Toll-like receptor pathways important for the expression of type 1-IFNs, such as IFN-α isoforms, which play a crucial role in eliminating viral infections 14272829. Immunoglobulin class switching from IgM to IgG and IgA is central to immunity against viruses and requires the activation of B-cells by T-cells via cytokine interactions with CD154/CD40L. Mutations in the CD40L gene have been observed in cases of inherited hyper-IgM X-linked immunodeficiences 27. In this context, CHIKV may be able to evade T-cell dependent IgG and IgA responses by attenuating CD40L gene expression. Such a mechanism has been postulated previously to explain hyper IgM syndrome associated with various viral infections 303132.

We report here a case of CHIKV infection with joint and bone erosion and persistent specific IgM nearly two years following infection. Transcriptomic and protein analysis revealed individual genes which could be implicated in the pathogenesis of chronic arthritis; these genes have not been associated previously with alphavirus-induced arthritis.

Consent

The patient has provided written consent to the use of his history for publication

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DMa took care of the patient. DMa and KE drafted the manuscript. BA and HT performed immunoglobulin assays. MMM, DMoy, DMa, JR and DMos performed the immunological analyses and evaluation. All authors reviewed the manuscript, contributed to its finalisation and approved the submitted version.

<p>Characterisation of reemerging Chikungunya virus</p> Sourisseau M Schilte C Casartelli N Trouillet C Guivel-Benhassine F PLoS Pathog 2007 3 e89 10.1371/journal.ppat.0030089 1904475 17604450 <p>Human muscle satellite cells as targets of Chikungunya virus</p> Ozden S Huerre M Riviere JP Coffey LL Afonso PV Mouly V PLoS ONE 2007 6 e527 10.1371/journal.pone.0000527 <p>An epidemic of virus disease in southern province, Tanganyika territory in 53; an additional note on chikungunya virus isolations and serum antibodies</p> Mason PJ Haddow AJ Trans R Soc Trop Med Hyg 1952 51 238 40 10.1016/0035-9203(57)90022-6 <p>Infectious diseases. Massive outbreak draws fresh attention to little known virus</p> Enserink M Science 2006 311 1085 10.1126/science.311.5764.1085a 16497896 <p>Emerging and resurging vector-borne diseases</p> Gratz NG Ann Rev Entomol 1999 44 51 75 10.1146/annurev.ento.44.1.51 <p>Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005-2006: a population-based survey</p> Sissoko D Moendandze A Malvy D Giry C Ezzedine K Solet J-L Pierre V PLoS ONE 2008 3 e3066 10.1371/journal.pone.0003066 2518850 18725980 <p>Post-Epidemic Chikungunya Disease on Reunion Island: Course of Rheumatic Manifestations and Associated Factors over a 15-Month Period</p> Sissoko D Malvy D Ezzedine K Renault P Moscetti F Ledrans M Pierre V PLoS Neglect Trop Dis 2009 3 e389 10.1371/journal.pntd.0000389 <p>Connective tissue metabolism in Chikungunya patients</p> Lokireddy S Vemula S Vadde R Virol J 2008 5 31 10.1186/1743-422X-5-31 2291039 18302795 <p>A destructive arthropathy following chikungunya virus arthritis - a possible association</p> Brighton SW Simson IW Clin Rheumatol 1984 3 253 8 10.1007/BF02030766 6088159 <p>Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African chikungunya viruses</p> Pastorino B Bessaud M Grandadam M Murri S Tolou HJ Peyrefitte CN J Virol Methods 2005 124 65 71 10.1016/j.jviromet.2004.11.002 15664052 <p>Rheumatoid arthritic syndrome after chikungunya fever</p> Fourie ED Morrison JG S Afr Med J 1979 56 130 2 494034 <p>Chikungunya viral arthropathy: a clinical description</p> Kennedy AC Fleming J Solomon L J Rheumatol 1980 7 231 6 7373626 <p>Chikungunya infection. An emerging rheumatism among travellers returned from the Indian Ocean Islands</p> Simon F Parola P Grandadam M Fourcade S Oliver M Brouqui P Hance P Kraemer P Ali Mohamed A de Lamballerie X Charrel R Tolou H Medicine 2007 86 123 37 10.1097/MD/0b013e31806010a5 17505252 <p>A mouse model for chikungunya: young age and inefficient type-1 interferon signaling are risk factors for severe disease</p> Couderc T Chrétien F Schilte C Disson O Madly B Benhassine-Guivel F Touret Y Barau G Cayet N Schuffenecker I Desprès P Arenzana-Seisdedos F Michault A Albert ML Lecuit M PLoS Pathog 2008 4 e29 10.1371/journal.ppat.0040029 2242832,2242832 18282093 <p>Alpha/beta interferon protects adult mice from fatal Sindbies virus infection and is an important determinant of cell and tissue tropism</p> Ryman KD Klimstra WB Nguyen KB Biron CA Johnston RE J Virol 2000 74 3066 78 10.1128/JVI.74.7.3366-3378.2000 <p>Clinical and pathologic aspects of arthritis due to Ross River and other alphaviruses</p> Suhrbier A La Linn M Curr Opin Rheumatol 2004 16 374 9 10.1097/01.bor.0000130537.76808.26 15201600 <p>Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis</p> Morrisson TE Whitmore AC Shabman RS Lidbury BA Mahalingam S Heise MT J Virol 2006 80 737 49 10.1128/JVI.80.2.737-749.2006 1346871 16378976 <p>Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus</p> Lidbury BA Rulli NE Suhrbier A Smith PN McColl SR Cunningham AL Tarkowski A van Rooijen N Fraser RJ Mahalingam S J Infect Dis 2008 197 1585 93 10.1086/587841 18433328 <p>Molecular and serological diagnosis of Chikungunya virus infection</p> Grivard P Le Roux K Laurent P Fianu A Perrau J Gigan J Hoarau G Grondin N Staikowsky F Favier F Michault A Pathol Biol (Paris) 2007 55 490 4 17920211 <p>Persistent arthralgia associated with Chikungunya virus: a study of 88 adults patients on Reunion Island</p> Borgherini G Poubeau P Jossaume A Gouix A Cotte L Michault A Arvin-Berod C Paganin F Clin Infect Dis 2008 47 469 79 10.1086/590003 18611153 <p>The pathogenetic role of HLA-B27 and its subtypes</p> Khan MA Matthieu A Sorrentino R Akkoc N Autoimmunity Rev 2007 6 183 9 10.1016/j.autrev.2006.11.003 <p>The viral autoimmunity relationship</p> Cohen A Schoenfeld Y Viral Immunol 1995 8 1 9 10.1089/vim.1995.8.1 8546799 <p>Common infections, idiotypic dysregulation, autoantibodies spread and induction of autoimmune diseases</p> Schoenfeld Y J Autoimmun 1996 9 235 9 10.1006/jaut.1996.0029 8738968 <p>Allelle-dependant similarity between viral and self-peptide presentation by HLA-B27 subtypes</p> Fiorillo MT Ruckert C Huhsmeyer M Sorrentino R Saenger W Ziegler A Uchanska-Ziegler B J Biol Chem 2005 280 2962 71 10.1074/jbc.M410807200 15537660 <p>Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells</p> Rot A von Andrian UH Annu Rev Immunol 2004 22 891 928 10.1146/annurev.immunol.22.012703.104543 15032599 <p>Biologic basis for interleukin-1 in disease</p> Dinarello CA Blood 1996 87 2095 147 8630372 <p>Recognition of viruses by innate immunity</p> Takeuchi O Akira S Immunol Rev 2007 220 214 24 10.1111/j.1600-065X.2007.00562.x 17979849 <p>Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors</p> Honda K Takaoda A Taniguchi T Immunity 2006 25 349 60 10.1016/j.immuni.2006.08.009 16979567 <p>Type I interferons in host defense</p> Stetson DB Medzhitov R Immunity 2006 25 373 81 10.1016/j.immuni.2006.08.007 16979569 <p>Hyper-IgM1 syndrome with interstitial pneumonia and diarrhaea caused by coxsackie virus B4 in a 3-month-old infant</p> Lin SC Shyur SD Ma YC Huang LH Lee WI Ann Allergy Asthma Immunol 2005 95 93 7 16095148 <p>Human immunodeficiency virus 1 Nef suppresses CD40-dependant immunoglobulin class switching in bystander B-cells</p> Qiao X He B Shin A Knowles DN Chadburn A Cerruti A Nat Immunol 2006 7 302 10 10.1038/ni1302 16429138 <p>CD40-ligand interactions promote trafficking of CD8+ T-cells into the brain and protection against West Nile encephalitis</p> Sitati E McCandless EE Klein RS Diamond MS J Virol 2007 81 9801 11 10.1128/JVI.00941-07 2045405 17626103

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/9/200/prepub